Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SXTP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.53% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.39M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 1.41 - 16.92 | Updated Date 06/30/2025 |
52 Weeks Range 1.41 - 16.92 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -21.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -745.61% |
Management Effectiveness
Return on Assets (TTM) -89.53% | Return on Equity (TTM) -183.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9658862 | Price to Sales(TTM) 4.22 |
Enterprise Value 9658862 | Price to Sales(TTM) 4.22 | ||
Enterprise Value to Revenue 14.51 | Enterprise Value to EBITDA 22.23 | Shares Outstanding 1472890 | Shares Floating 1289266 |
Shares Outstanding 1472890 | Shares Floating 1289266 | ||
Percent Insiders 4.97 | Percent Institutions 7.3 |
Analyst Ratings
Rating 1 | Target Price 7 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
60 Degrees Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutics for infectious diseases. The company was founded in 2011 and is based in Cincinnati, Ohio. The company's primary focus has been on developing and commercializing drugs to prevent and treat infectious diseases.
Core Business Areas
- Prevention and Treatment of Infectious Diseases: Focuses on developing and commercializing therapeutics and prophylactic measures for infectious diseases, particularly those relevant to travelers and global health.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization. The structure typically includes departments for research and development, clinical trials, regulatory affairs, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Arakoda (tafenoquine): Arakoda is a prescription medicine used to prevent malaria. The market share for tafenoquine-based malaria prevention is growing, however specific figures are not publicly available. The drug competes with other malaria preventatives such as atovaquone-proguanil (Malarone), doxycycline, and mefloquine. Revenue from Arakoda is the primary revenue stream for 60 Degrees Pharma.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the segment focused on infectious diseases, is driven by global health concerns, travel-related illnesses, and emerging pathogens. This sector sees continuous research and development efforts to combat drug resistance and create new treatments.
Positioning
60 Degrees Pharmaceuticals, Inc. positions itself as a specialist in travel medicine and infectious disease prevention. Their advantage lies in their focus and specialized products.
Total Addressable Market (TAM)
The global market for malaria prevention and treatment is estimated to be in the billions of dollars. 60 Degrees Pharma is positioned to capture a segment of this market with Arakoda, particularly targeting travelers and military personnel. Exact figures depend on disease outbreak patterns and other variables.
Upturn SWOT Analysis
Strengths
- Specialized focus on infectious diseases
- Proprietary drug (Arakoda)
- Established regulatory pathway for approval
Weaknesses
- Limited product portfolio
- Reliance on a single product for revenue
- Smaller size compared to major pharmaceutical companies
Opportunities
- Expanding into new geographic markets
- Developing new drugs for other infectious diseases
- Partnering with larger pharmaceutical companies
Threats
- Competition from established malaria preventatives
- Changes in travel patterns and disease prevalence
- Regulatory hurdles for new drug approvals
Competitors and Market Share
Key Competitors
- Sanofi (SNY)
- GlaxoSmithKline (GSK)
- Novartis (NVS)
Competitive Landscape
60 Degrees Pharmaceuticals, Inc. faces strong competition from established pharmaceutical companies with broader product portfolios and larger distribution networks. Its advantage lies in its specialized focus and proprietary drug, Arakoda.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to assess due to the company being privately held. Growth is dependent on the success of Arakoda sales and any future product development.
Future Projections: Future growth is dependent on successful commercialization of Arakoda and potential new product developments. Projections are not publicly available.
Recent Initiatives: Recent initiatives likely include expanding marketing and distribution of Arakoda and pursuing research and development opportunities for new infectious disease therapeutics.
Summary
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on infectious diseases, primarily malaria prevention. Their main strength lies in their proprietary drug, Arakoda, but they face challenges due to their limited product portfolio and competition from larger companies. Opportunities exist in expanding into new markets and developing new drugs. Careful management of competition and regulatory hurdles is critical for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings of competitors
- Industry reports
Disclaimers:
The information provided is based on publicly available data and may not be entirely accurate or complete. This analysis is not financial advice. Market share percentages are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 60 Degrees Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2023-07-12 | Chairman, CEO & President Dr. Geoffrey Stuart Dow Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.60degreespharma.com |
Full time employees 3 | Website https://www.60degreespharma.com | ||
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.